Popular Articles

Three Rivers Announces Positive Results From Phase 3 DIRECT Trial Of Once-Daily INFERGEN(R) With Ribavirin In Hepatitis C Virus Treatment Failures
Three Rivers Pharmaceuticals announced positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University, and colleagues at 44 centers in the United States. The primary endpoint of increased sustained virological response (SVR), was achieved demonstrating that INFERGEN provides a second chance to those HCV patients failing to respond to standard, first-line therapy of pegylated interferon (PEG-IFN) plus ribavirin (RBV). "The retreatment of PEG-IFN/RBV nonresponders with INFERGEN and RBV is safe and efficacious and can be considered a retreatment strategy for patients failing previous therapy with PEG-IFN/RBV, especially in interferon-sensitive patients with lower baseline fibrosis scores," stated Dr. Bruce Bacon the lead Investigator for the study.
buy viagra
Safer Transportation Of A Child With Special Needs
A new study by researchers from the Automotive Safety Program at Riley Hospital for Children and Indiana University School of Medicine published online July 13, 2009 in the journal Pediatrics reports that the parents of children with special health care needs are doing a good job with the selection of the appropriate child car seat but still need help in using it correctly.
News of the day
Study Sees Transient Heart Dysfunction In Some Long-Distance Runners
A new study using advanced cardiac imaging technology indicates that cardiac abnormalities experienced by some marathon runners following competition are temporary, and do not result in damage to the heart muscle. The study, conducted by researchers at the University of Manitoba, marked the first use of cardiac magnetic resonance imaging, or CMR, in a post-marathon setting.
Public Health

CSC Offers Medicare Secondary Payer Reporting To Health Plans

CSC (NYSE: CSC) announced that it has expanded its FirstPortfolio solution"s business process outsourcing (BPO) capabilities to include fully integrated Medicare Secondary Payer (MSP) reporting for healthcare payers. FirstPortfolio provides users with a collection of applications hosted and maintained by CSC. MSP status reporting, which requires the identification and reporting of all potential Medicare beneficiaries within commercial health plans to the Centers for Medicare and Medicaid Services (CMS), becomes mandatory for a wide variety of insurers and plan administrators in October 2009. With CSC"s MSP reporting capability, health plan organizations can expand BPO application portfolios to meet implementation timelines and address gaps that may impede compliance with new CMS regulations. "We are pleased to present this timely business capability to the health plan market," said Deward Watts, president of CSC"s Healthcare Group. "This addition to FirstPortfolio provides an end-to-end solution that allows our customers to meet CMS deadlines as well as leverage CSC"s health plan domain knowledge and regulatory and compliance experience." CSC"s Healthcare Group, which serves healthcare providers, health plans, pharmaceutical and medical device manufacturers, and allied industries around the world, is a global leader in transforming the healthcare industry through the effective use of information to improve healthcare outcomes, decision-making and operating efficiency. About CSC CSC is a global leader in providing technology-enabled solutions and services through three primary lines of business. These include Business Solutions & Services, Managed Services Sector and the North American Public Sector. CSC"s advanced capabilities include systems design and integration, information technology and business process outsourcing, applications software development, Web and application hosting, mission support and management consulting. Headquartered in Falls Church, Va., CSC has approximately 92,000 employees and reported revenue of $16.74 billion for the 12 months ended April 3, 2009. CSC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):